Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy

Ann Ophthalmol. 1992 Mar;24(3):99-103.

Abstract

This pilot project suggested that angiotensin-converting enzyme (ACE) inhibitors may have an effect on delaying or reversing diabetic retinopathy. One patient who had Grade 5 (preproliferative) retinopathy improved to Grade 2 (microaneurysms only) after two years of treatment. Of the 450 patients followed in our eye and kidney clinic, no other patient showed a similar reversal from Grade 5 retinopathy without treatment. Improvement by one or more grades was seen in three other patients with variable grades of retinopathy after a mean of 3.3 years of treatment. Improvement was not related consistently to a decrease in blood pressure (0 of 4), better glycemic control (2 of 4), or reduction in albumin excretion rate (0 of 4). Proper double-blind controlled studies are needed to prove the effect of ACE inhibitors on diabetic microangiopathy of the eye.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Adult
  • Captopril / therapeutic use*
  • Creatinine / blood
  • Diabetes Mellitus, Type 1 / drug therapy
  • Diabetic Retinopathy / drug therapy*
  • Female
  • Glycated Hemoglobin / analysis
  • Humans
  • Male
  • Pilot Projects

Substances

  • Glycated Hemoglobin A
  • Captopril
  • Creatinine